Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1954 1
1963 1
1965 1
1977 1
1986 3
1990 2
1994 1
1995 1
1996 5
1997 4
1998 5
1999 6
2000 9
2001 10
2002 3
2003 12
2004 5
2005 4
2006 6
2007 17
2008 17
2009 9
2010 14
2011 23
2012 22
2013 24
2014 22
2015 29
2016 14
2017 18
2018 22
2019 28
2020 21
2021 29
2022 25
2023 20
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

403 results

Results by year

Filters applied: . Clear all
Page 1
Evaluation of the Abdala Vaccine: Antibody and Cellular Response to the RBD Domain of SARS-CoV-2.
Islas-Vazquez L, Alvarado-Alvarado YC, Cruz-Aguilar M, Velazquez-Soto H, Villalobos-Gonzalez E, Ornelas-Hall G, Perez-Tapia SM, Jimenez-Martinez MC. Islas-Vazquez L, et al. Vaccines (Basel). 2023 Nov 30;11(12):1787. doi: 10.3390/vaccines11121787. Vaccines (Basel). 2023. PMID: 38140191 Free PMC article.
Abdala is a recently released RBD protein subunit vaccine against SARS-CoV-2. A few countries, including Mexico, have adopted Abdala as a booster dose in their COVID-19 vaccination schemes. Despite that, most of the Mexican population has received full-scheme vaccin …
Abdala is a recently released RBD protein subunit vaccine against SARS-CoV-2. A few countries, including Mexico, have adopted Abda …
Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study.
Labeau SO, Afonso E, Benbenishty J, Blackwood B, Boulanger C, Brett SJ, Calvino-Gunther S, Chaboyer W, Coyer F, Deschepper M, François G, Honore PM, Jankovic R, Khanna AK, Llaurado-Serra M, Lin F, Rose L, Rubulotta F, Saager L, Williams G, Blot SI; DecubICUs Study Team; European Society of Intensive Care Medicine (ESICM) Trials Group Collaborators. Labeau SO, et al. Intensive Care Med. 2021 Feb;47(2):160-169. doi: 10.1007/s00134-020-06234-9. Epub 2020 Oct 9. Intensive Care Med. 2021. PMID: 33034686 Free PMC article.
Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study.
Más-Bermejo PI, Dickinson-Meneses FO, Almenares-Rodríguez K, Sánchez-Valdés L, Guinovart-Díaz R, Vidal-Ledo M, Galbán-García E, Olivera-Nodarse Y, Morgado-Vega I, Dueñas-Carrera S, Pujol M, Hernández-Bernal F, Limonta-Fernández M, Guillén-Nieto G, Muzio-González VL, Ayala-Ávila M. Más-Bermejo PI, et al. Lancet Reg Health Am. 2022 Dec;16:100366. doi: 10.1016/j.lana.2022.100366. Epub 2022 Sep 24. Lancet Reg Health Am. 2022. PMID: 36185968 Free PMC article.
BACKGROUND: COVID-19 vaccines have proven safe and efficacious in reducing severe illness and death. Cuban protein subunit vaccine Abdala has shown safety, tolerability and efficacy (92.3% [95% CI: 85.7-95.8]) against SARS-CoV-2 in clinical trials. This study aimed to esti …
BACKGROUND: COVID-19 vaccines have proven safe and efficacious in reducing severe illness and death. Cuban protein subunit vaccine Abdala …
Cuba's National Regulatory Authority & COVID-19: Olga Lidia Jacobo-Casanueva MS Director, Center for State Control of Medicines and Medical Devices (CECMED).
Aguilar-Guerra TL, Fajardo-Díaz EM, Gorry C. Aguilar-Guerra TL, et al. MEDICC Rev. 2021 Jul-Oct;23(3-4):9-14. doi: 10.37757/MR2021.V23.N3.3. Epub 2021 Aug 22. MEDICC Rev. 2021. PMID: 34516531 Free article.
At the time of this writing, more than 10 million Cubans (nearly 90% of the country's population), had received at least their first dose of Soberana 02 or Abdala, two of five vaccine candidates for SARS-CoV-2 developed and produced on the island. ...Building on dec …
At the time of this writing, more than 10 million Cubans (nearly 90% of the country's population), had received at least their first …
Vaccines and Public Trust: Containing COVID-19 in Cuba.
Gorry C. Gorry C. MEDICC Rev. 2022 Jan 31;24(1):9-13. doi: 10.37757/MR2022.V24.N1.11. MEDICC Rev. 2022. PMID: 35157633 Free article.
A pioneer of Cuba's biotechnology sector, she is an immunologist with a doctorate in biological sciences. Her professional trajectory began researching the genetically engineered hepatitis B surface antigen that led to the development of Cuba's recombinant hepatitis …
A pioneer of Cuba's biotechnology sector, she is an immunologist with a doctorate in biological sciences. Her professional trajectory …
BLV: lessons on vaccine development.
Abdala A, Alvarez I, Brossel H, Calvinho L, Carignano H, Franco L, Gazon H, Gillissen C, Hamaidia M, Hoyos C, Jacques JR, Joris T, Laval F, Petersen M, Porquet F, Porta N, Ruiz V, Safari R, Suárez Archilla G, Trono K, Willems L. Abdala A, et al. Retrovirology. 2019 Oct 7;16(1):26. doi: 10.1186/s12977-019-0488-8. Retrovirology. 2019. PMID: 31590667 Free PMC article. Review.
Meditation: Evidence Map of Systematic Reviews.
Schlechta Portella CF, Ghelman R, Abdala V, Schveitzer MC, Afonso RF. Schlechta Portella CF, et al. Front Public Health. 2021 Dec 2;9:742715. doi: 10.3389/fpubh.2021.742715. eCollection 2021. Front Public Health. 2021. PMID: 34926371 Free PMC article.
403 results